Search KLH Site
Find Articles by Tags
Addiction (18) Adjuvant - Alum (1) Adjuvant - GPI-0100 (1) Adjuvant - IL-4 (9) Adjuvant GM-CSF (16) Adjuvant KLH (4) Adjuvant Oil / Surfactant (4) Adjuvant QS-21 (25) Age & Physical Activity (3) Allergen-specific immunotherapy (1) Allergy – Pollen (2) Alzheimer's Disease (3) Antibody Response (35) Antibody Response IgA (14) Antibody Response IgE (6) Antibody Response IgG (106) Antibody Response IgM (71) Antibody Response IgY (1) APEC (1) Assay - Bioassay (2) Assay - Carbohydrate Microarray (1) Assay - ELISA (55) Assay - ELISPOT (7) Assay - Immunoassay (8) Assay - InVitro (18) Assay - InVivo (1) Atopic Dermatitis (1) Autoimmune Disease (1) B-epitope (1) Bone Marrow Transplant (6) Cancer (6) Cancer - Bladder (16) Cancer - Brain & CNS (8) Cancer - Breast (15) Cancer - Cervical (1) Cancer - Colorectal (10) Cancer - Esophageal (1) Cancer - Female Reproductive (7) Cancer - Leukemia (2) Cancer - Lung (4) Cancer - Lymphoma (25) Cancer - Melanoma (37) Cancer - Mesothelioma (1) Cancer - Myeloma (15) Cancer - Other (2) Cancer - Ovarian (3) Cancer - Pancreas (1) Cancer - Pediatric (3) Cancer - Peritoneal (2) Cancer - Prostate (9) Cancer - Renal (13) Cancer - Sarcoma (2) Clostridium difficile (5) Crohn's Disease (2) Cross-Reactive Antigens (6) Delayed-type hypersensitivity response (1) Dendritic Cell (66) Developmental (10) Diabetes (2) Disease Resistence (1) DNP-Ficoll (2) DTH (67) Environmental (15) Escherichia coli (1) Fingolimod (Gilenya) (1) Healthy Volunteers (18) HealthyAntibody Response - IgA (1) Hepatitis (2) HIV (11) HPV (3) Husbandry (3) Hypertension (1) id-KLH (29) IL 1 (4) IL 12 (2) IL 15 (1) IL 2 (10) IL 5 (1) IL 6 (1) IL 7 (1) Immune Disease - Autoimmune (13) Immune Disease - Primary (2) Immune Disease – Secondary (1) Immune Response - Cellular (187) Immune Response - Humoral (259) Immune Response Humoral (2) Immunotoxicity (37) Infection (1) Infectious Disease (5) Inflammatory Disease (1) Intradermal KLH (1) Kidney (1) KLH-BEC2 (1) KLH-BP16 (1) KLH-BPO (1) KLH-Conjugate (69) KLH-EGFR (2) KLH-FITC (1) KLH-Ganglioside (16) KLH-Globo H (7) KLH-GM2 (1) KLH-hD1 (1) KLH-HGP-30 (1) KLH-IL (1) KLH-Kinoid (8) KLH-Lewis Y (3) KLH-MUC (8) KLH-Oxycodone (2) KLH-sTn (9) KLH-TF (5) KLH-TN (3) Model - Canine (6) Model - Guinea Pig (10) Model - Livestock (10) Model - Mouse (73) Model - Other (32) Model - Primate (12) Model - Rat (51) Multiple Sclerosis (1) Nasal (3) Natrural Antibody (1) Neonatal (2) NK Cells (1) NSAID (1) Oral KLH (9) Oxycodone (3) Parasitic Disease (6) Pediatric (1) Plant-made (2) PLNA (1) Population Density (3) Psoriasis (1) Review Article (2) Rheumatoid Arthritis (11) Rituximab (Rituxan) (4) Russian thistle (1) Sal k 1 (1) Stress (8) Systemic Lupus Erythematosus (SLE) (7) TACA (2) TDAR (127) Therapeutics - KLH Alone (15) Transplant (6) Ultra Violet radiation (1) Uveitis (1) VEGF (3) Veterinary (1)
Terms and Privacy

KLH in Publications

Publications of scientific research involving KLH. Abstracts or full text articles are available by link to outside sites. If you know of a KLH-related publication that is not yet on KLH Site™, let us know.

(in order by date)

Entries in Adjuvant GM-CSF (16)

Saturday
Jun202009

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.

Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P.

J Clin Oncol. 2009 Jun 20;27(18):3036-43. Epub 2009 May 4.

Thursday
Jan012009

Prolonged idiotypic vaccination against follicular lymphoma

Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M.

Leuk Lymphoma. 2009 Jan;50(1):47-53

Thursday
Jan012009

Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines

Kamran Kafi, David J. Betting, Reiko E. Yamada, Michael Bacica, Kristopher K. Steward, and John M. Timmerman. 

Mol Immunol. 2009 January; 46(3): 448–456

Saturday
Nov012008

Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors.

Suminoe A, Matsuzaki A, Hattori H, Koga Y, Hara T.

Pediatr Transplant. Epub 2008 Nov 1.  2009 Sep;13(6):746-53.

Tuesday
Jul012008

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.

Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ.

J Immunother. 2008 Jul-Aug;31(6):591-8.

Friday
Feb012008

Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo

Suzanne N. Franki, Kristopher K. Steward, David J. Betting, Kamran Kafi, Reiko E. Yamada, and John M. Timmerman.

Blood. 2008 February 1; 111(3): 1504–1511.

Wednesday
Jun012005

Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.

Thursday
Jul012004

Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.

Curti A, Isidori A, Ferri E, Terragna C, Neyroz P, Cellini C, Ratta M, Baccarani M, Lemoli RM.

Leuk Lymphoma. 2004 Jul;45(7):1419-28.

Thursday
Jul012004

Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.  

Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M.

Leukemia. 2004 Jan;18(1):139-45.

Wednesday
Nov052003

Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma

Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C, Lett M.

Cancer Immunol Immunother. 2004 Feb;53(2):125-34. Epub 2003 Nov 5.

Wednesday
Oct012003

Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.

Reichardt VL, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P.

Haematologica. 2003 Oct;88(10):1139-49.

Saturday
Dec012001

Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.  

Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mulé JJ.

Cancer Res. 2001 Dec 1;61(23):8513-9.

Thursday
Jul151999

Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.

Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A.

Blood. 1999 Jul 15;94(2):673-83.

Thursday
Apr011999

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study

Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R.

Blood. 1999 Apr 1;93(7):2411-9.

Sunday
Mar011998

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D.

Nat Med. 1998 Mar;4(3):328-32.

Thursday
Apr011993

Cytokine-induced suppression and potentiation of hapten-specific immediate hypersensitivity responses.

Auci DL, Kleiner G, Sheikh A, Acosta E, Athanassiadies TJ, Murali MR, Durkin HG.

Immunol Invest. 1993 Apr;22(3):205-18.